268 related articles for article (PubMed ID: 7693103)
1. BCR/ABL oncoprotein-targeted antitumor activity of antisense oligodeoxynucleotides complementary to bcr/abl mRNA and herbimycin A, an antagonist of protein tyrosine kinase: inhibitory effects on in vitro growth of Ph1-positive leukemia cells and BCR/ABL oncoprotein-associated transformed cells.
Okabe M; Kunieda Y; Miyagishima T; Kobayashi M; Kurosawa M; Itaya T; Sakurada K; Miyazaki T
Leuk Lymphoma; 1993 Jul; 10(4-5):307-16. PubMed ID: 7693103
[TBL] [Abstract][Full Text] [Related]
2. Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
Okabe M; Uehara Y; Miyagishima T; Itaya T; Tanaka M; Kuni-Eda Y; Kurosawa M; Miyazaki T
Blood; 1992 Sep; 80(5):1330-8. PubMed ID: 1515646
[TBL] [Abstract][Full Text] [Related]
3. New insight into oncoprotein-targeted antitumor effect: herbimycin A as an antagonist of protein tyrosine kinase against Ph1-positive leukemia cells.
Okabe M; Uehara M
Leuk Lymphoma; 1993 Dec; 12(1-2):41-9. PubMed ID: 8161936
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Philadelphia-chromosome-positive human leukemia in SCID mouse model with herbimycin A, bcr-abl tyrosine kinase activity inhibitor.
Honma Y; Matsuo Y; Hayashi Y; Omura S
Int J Cancer; 1995 Mar; 60(5):685-8. PubMed ID: 7860143
[TBL] [Abstract][Full Text] [Related]
5. Effect of herbimycin A, an inhibitor of tyrosine kinase, on protein tyrosine kinase activity and phosphotyrosyl proteins of Ph1-positive leukemia cells.
Okabe M; Kawamura K; Miyagishima T; Itaya T; Goodwyn D; Shoji M; Vogler WR; Sakurada K; Uehara M; Miyazaki T
Leuk Res; 1994 Mar; 18(3):213-20. PubMed ID: 7511193
[TBL] [Abstract][Full Text] [Related]
6. Effects of herbimycin A and its derivatives on growth and differentiation of Ph1-positive acute lymphoid leukemia cell lines.
Sato S; Honma Y; Hozumi M; Hayashi Y; Matsuo Y; Shibata K; Omura S; Hino K; Tomoyasu S; Tsuruoka N
Leuk Res; 1994 Mar; 18(3):221-8. PubMed ID: 8139288
[TBL] [Abstract][Full Text] [Related]
7. In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells.
Okabe M; Uehara Y; Noshima T; Itaya T; Kunieda Y; Kurosawa M
Leuk Res; 1994 Nov; 18(11):867-73. PubMed ID: 7967714
[TBL] [Abstract][Full Text] [Related]
8. Control of growth and differentiation of Philadelphia chromosome-positive leukemia cells by tyrosine kinase inhibitors.
Honma Y; Kasukabe T; Hozumi M
Tohoku J Exp Med; 1992 Oct; 168(2):387-91. PubMed ID: 1306324
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.
Skorski T; Kanakaraj P; Nieborowska-Skorska M; Ratajczak MZ; Wen SC; Zon G; Gewirtz AM; Perussia B; Calabretta B
Blood; 1995 Jul; 86(2):726-36. PubMed ID: 7606002
[TBL] [Abstract][Full Text] [Related]
11. Herbimycin A accelerates the induction of apoptosis following etoposide treatment or gamma-irradiation of bcr/abl-positive leukaemia cells.
Riordan FA; Bravery CA; Mengubas K; Ray N; Borthwick NJ; Akbar AN; Hart SM; Hoffbrand AV; Mehta AB; Wickremasinghe RG
Oncogene; 1998 Mar; 16(12):1533-42. PubMed ID: 9569020
[TBL] [Abstract][Full Text] [Related]
12. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.
Shiotsu Y; Neckers LM; Wortman I; An WG; Schulte TW; Soga S; Murakata C; Tamaoki T; Akinaga S
Blood; 2000 Sep; 96(6):2284-91. PubMed ID: 10979978
[TBL] [Abstract][Full Text] [Related]
13. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
[TBL] [Abstract][Full Text] [Related]
15. Unexpected heterogeneity of BCR-ABL fusion mRNA detected by polymerase chain reaction in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Hooberman AL; Carrino JJ; Leibowitz D; Rowley JD; Le Beau MM; Arlin ZA; Westbrook CA
Proc Natl Acad Sci U S A; 1989 Jun; 86(11):4259-63. PubMed ID: 2498881
[TBL] [Abstract][Full Text] [Related]
16. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
17. Bcr: a negative regulator of the Bcr-Abl oncoprotein.
Wu Y; Ma G; Lu D; Lin F; Xu HJ; Liu J; Arlinghaus RB
Oncogene; 1999 Aug; 18(31):4416-24. PubMed ID: 10442632
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of abl oncogene tyrosine kinase induces erythroid differentiation of human myelogenous leukemia K562 cells.
Honma Y; Okabe-Kado J; Kasukabe T; Hozumi M; Umezawa K
Jpn J Cancer Res; 1990 Nov; 81(11):1132-6. PubMed ID: 2125038
[TBL] [Abstract][Full Text] [Related]
19. Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate.
Anafi M; Gazit A; Zehavi A; Ben-Neriah Y; Levitzki A
Blood; 1993 Dec; 82(12):3524-9. PubMed ID: 7505115
[TBL] [Abstract][Full Text] [Related]
20. Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line.
Snyder DS; Wu Y; Wang JL; Rossi JJ; Swiderski P; Kaplan BE; Forman SJ
Blood; 1993 Jul; 82(2):600-5. PubMed ID: 8329715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
